Ceftazidime is NOT Recommended for Chronic Sinus Discharge in Adults
Ceftazidime should not be used for chronic sinus discharge in adults. This third-generation cephalosporin is not indicated for chronic rhinosinusitis (CRS) and does not provide appropriate coverage for the typical pathogens involved in this condition.
Why Ceftazidime is Inappropriate
Ceftazidime's spectrum of activity is mismatched for chronic sinus disease:
Wrong pathogen coverage: Ceftazidime is primarily designed for Gram-negative bacteria, particularly Pseudomonas aeruginosa 1, 2. The typical pathogens in chronic sinusitis are Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis 3.
Poor Gram-positive activity: Ceftazidime has notably weaker activity against S. pneumoniae compared to first and second-generation cephalosporins 4. This is a critical limitation since S. pneumoniae is a primary pathogen in sinusitis.
Not mentioned in sinusitis guidelines: Multiple comprehensive sinusitis guidelines from 2005-2025 make no mention of ceftazidime as a treatment option 3, 5, 3, 5, 6, 7.
Appropriate Treatment for Chronic Sinus Discharge
First, Clarify the Diagnosis
Chronic sinus discharge lasting >12 weeks requires distinguishing between:
- Chronic rhinosinusitis (CRS): Persistent inflammation requiring non-antibiotic management
- Acute bacterial exacerbation of CRS: May warrant antibiotics
- Recurrent acute bacterial rhinosinusitis: Multiple discrete episodes
For Acute Bacterial Exacerbations Requiring Antibiotics
First-line therapy: Amoxicillin-clavulanate 5, 6
- Dosing: 875-1000 mg twice daily for adults
- Duration: 5-10 days (guidelines vary; most recommend 5-7 days for uncomplicated cases)
- Rationale: Provides coverage for β-lactamase-producing H. influenzae and M. catarrhalis (present in 50% and 90-100% of strains, respectively) 3
Alternative agents (for penicillin allergy or intolerance):
- Doxycycline 100 mg twice daily 5
- Respiratory fluoroquinolones (levofloxacin 500 mg daily, moxifloxacin 400 mg daily) 3
Critical Point About Chronic Rhinosinusitis
Antibiotics are NOT recommended for CRS without acute bacterial exacerbation 6. The 2025 AAO-HNS guideline explicitly recommends against empiric antibiotics for CRS solely as a third-party requirement for surgery or imaging 6.
Common Pitfalls to Avoid
Using first-generation cephalosporins (cephalexin, cefadroxil): These have poor coverage for H. influenzae and are inappropriate 3
Using cefixime or ceftibuten: These third-generation cephalosporins have poor activity against S. pneumoniae, especially penicillin-resistant strains, and should not be used 3
Prescribing antibiotics for viral rhinosinusitis: Most acute rhinosinusitis is viral and self-limited; antibiotics cause more harm than benefit (number needed to harm = 8 vs. number needed to treat = 18) 5
Prolonged antibiotic courses for CRS: This promotes resistance without improving outcomes 6
When Ceftazidime IS Appropriate
Ceftazidime's role is limited to serious infections with documented Gram-negative pathogens, particularly Pseudomonas: